| __timestamp | Iovance Biotherapeutics, Inc. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 4167274 |
| Thursday, January 1, 2015 | 999000 | 5247851 |
| Friday, January 1, 2016 | 978000 | 4925118 |
| Sunday, January 1, 2017 | 952000 | 14930297 |
| Monday, January 1, 2018 | 956000 | 25371768 |
| Tuesday, January 1, 2019 | 8122999 | 23921274 |
| Wednesday, January 1, 2020 | 8712000 | 25338236 |
| Friday, January 1, 2021 | 13980000 | 20182966 |
| Saturday, January 1, 2022 | 21135000 | 17562000 |
| Sunday, January 1, 2023 | 10755000 | 25212000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Pharming Group N.V. and Iovance Biotherapeutics, Inc. from 2014 to 2023. Over this period, Pharming Group N.V. consistently reported higher costs, peaking in 2018 with a 510% increase from 2014. In contrast, Iovance Biotherapeutics, Inc. experienced a more volatile trajectory, with a significant surge in 2022, marking a 125% rise from the previous year. This fluctuation highlights the dynamic nature of biotech investments, where strategic decisions and market conditions can dramatically impact financial outcomes. As the industry continues to innovate, these insights provide a window into the financial health and strategic priorities of these key players.
Novo Nordisk A/S vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Zoetis Inc. vs Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Incyte Corporation and Pharming Group N.V.'s Expenses
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Iovance Biotherapeutics, Inc.
Cost of Revenue Trends: Jazz Pharmaceuticals plc vs Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Pharming Group N.V. vs Xenon Pharmaceuticals Inc.
Cost of Revenue Comparison: Pharming Group N.V. vs PTC Therapeutics, Inc.
Cost of Revenue Trends: Pharming Group N.V. vs HUTCHMED (China) Limited
Cost Insights: Breaking Down Pharming Group N.V. and Galapagos NV's Expenses
Comparing Cost of Revenue Efficiency: Grifols, S.A. vs Iovance Biotherapeutics, Inc.
Corcept Therapeutics Incorporated vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: HUTCHMED (China) Limited vs Iovance Biotherapeutics, Inc.